NextCure, Inc. (NXTC): Price and Financial Metrics


NextCure, Inc. (NXTC): $1.63

-0.04 (-2.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NXTC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NXTC Stock Price Chart Interactive Chart >

Price chart for NXTC

NXTC Price/Volume Stats

Current price $1.63 52-week high $5.68
Prev. close $1.67 52-week low $1.16
Day low $1.59 Volume 53,000
Day high $1.65 Avg. volume 129,252
50-day MA $1.48 Dividend yield N/A
200-day MA $3.23 Market Cap 45.27M

NextCure, Inc. (NXTC) Company Bio


NextCure, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.


NXTC Latest News Stream


Event/Time News Detail
Loading, please wait...

NXTC Latest Social Stream


Loading social stream, please wait...

View Full NXTC Social Stream

Latest NXTC News From Around the Web

Below are the latest news stories about NEXTCURE INC that investors may wish to consider to help them evaluate NXTC as an investment opportunity.

Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | December 2, 2022

NextCure to Present at Upcoming Investor Conferences

BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the following investor conferences: Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 3:30 pm (ET) in New York City JMP Securities Hematology and Oncology Summit (Virtual) on

Yahoo | November 22, 2022

NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates

NextCure Inc (NASDAQ: NXTC) and LegoChem Biosciences Inc announced a collaboration and co-development agreement to generate a B7-H4 antibody-drug conjugate (ADC) and options for two additional targets. The B7-H4 ADC will utilize NextCure's B7-H4 antibody and LCB's ConjuAllTM ADC technology. Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products. Related: NextCure Launches Early-Stage Study For NC762 In Solid Tum

Yahoo | November 16, 2022

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

BELTSVILLE, Md. and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets. The B7-H4 ADC will utilize NextCure’s B7-H4 antibody and LCB’s ConjuAllTM ADC technology. Under the terms of the agreement, both parties will equally share the costs to develop the

Yahoo | November 15, 2022

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, will present initial clinical data from a Phase 1 cl

Yahoo | November 7, 2022

Read More 'NXTC' Stories Here

NXTC Price Returns

1-mo 9.40%
3-mo -17.68%
6-mo -65.39%
1-year -69.53%
3-year -96.26%
5-year N/A
YTD 15.60%
2022 -76.50%
2021 -44.95%
2020 -80.65%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6712 seconds.